Back to Clinical Trials Overview

Back To Cancer Clinical Trials

Your search for "Multiple Myeloma" returned 38 results:


An Open-label, Multicenter Rollover Study to Allow Continued Access to Filanesib (ARRY-520) for Patients with Multiple Myeloma Who Are Currently Receiving Filanesib in Studies Sponsored by Array BioPharma Inc.
Principal Investigator(s): Dr. Ajai Chari

A Phase II Controlled Trial of a Single ProHema-CB unit (Ex Vivo CXCR4-Upregulated CD34+ Hematopoietic Progenitor Cells, Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative Conditioning For Patients Age 15-55 Years With Hematologic Malignancies
Principal Investigator(s): Luis M. Isola

A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy
Principal Investigator(s): Dr. Ajai Chari

A Phase 1 Study of ARRY-520 and Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Principal Investigator(s): Ajai Chari

A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Principal Investigator(s): Dr. Ajai Chari

An Open-Label Treatment Use Protocol for Daratumumab in Subjects with Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and an Immunomodulatory Agent) or are Double Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent
Principal Investigator(s): Dr. Ajai Chari

A Phase 2 Single Arm Study of Elotuzumab in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Multiple Myeloma Relapsed or Refractory to Prior Treatment with Lenalidomide
Principal Investigator(s): Dr. Sundar Jagannath

A Phase II , Single-Center, Open Label study of Oral Panobinostat (LBH589) when administered in combination with Lenalidomide and weekly Dexamethasone in patients with multiple myeloma
Principal Investigator(s): Ajai Chari

Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects with Relapsed and Refractory Multiple Myeloma
Principal Investigator(s): Dr. Sundar Jagannath

A Phase I/IIa multi-dose escalation study of BT062 in combination with Lenalidomide and Dexamethasone in subjects with relapsed or relapsed/refractory Multiple Myeloma
Principal Investigator(s): Sundar Jagannath

A Phase 1b Study of SAR65098 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma
Principal Investigator(s): Dr. Ajai Chari

A Phase Ib Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral AKT Inhibitor GSK2110183 Administered in Combination with Bortezomib and Dexamethasone in Subjects with Relapsed/Refractory Multiple Myeloma
Principal Investigator(s): Ajai Chari

A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications
Principal Investigator(s): Luis M. Isola

BMT CTN 1302: A Multicenter Phase II, Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma
Principal Investigator(s): Dr. Keren Osman

A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age
Principal Investigator(s): Sundar Jagannath

Phase II Study of the Addition of Azacitidine (IND #87574, NSC #102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients with AML
Principal Investigator(s): Luis M. Isola

An Open-label, Multicenter, Phase 2 Trial Investigating the Efficacy and Safety of Daratumumab in Subjects with Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and IMiD) or are Double Refractory to a Proteasome Inhibitor and an IMiD
Principal Investigator(s): Ajai Chari

Phase 1 study of Elotuzumab in combination with autologous stem cell transplantation and lenalidomide maintenance for multiple myeloma
Principal Investigator(s): Dr. Hearn Jay Cho

A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma
Principal Investigator(s): Dr. Ajai Chari

A Phase 1b/2 Multicenter, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of ACY-1215 (ricolinostat) in Combination with Pomalidomide and Low-dose Dexamethasone in Patients with Relapsed-and-Refractory Multiple Myeloma
Principal Investigator(s): Dr. Sundar Jagannath

A Phase 1b Multicenter, Open-Label Study to Determine the Recommended Dose and Regimen of Durvalumab (MEDI4736) Either as Monotherapy or in Combination with Pomalidomide (POM) with or without Lowdose Dexamethasone (DEX) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)
Principal Investigator(s): Dr. Sundar Jagannath

A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects with Relapsed or Relapsed and Refractory Multiple Myeloma
Principal Investigator(s): Sundar Jagannath

A multicenter safety study of unlicensed, investigational cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patients
Principal Investigator(s): Luis M. Isola

A Phase Ib Study of the Saftey and Pharmacokinetics of MPDL3280A (Anti-PD-L1 Antibody) Alone or in Combination with Lenalidomide in Patients with Multiple Myeloma (Relapsed and Post-Autologous Stem Cell Transplantation)
Principal Investigator(s): Dr. Hearn Jay Cho

Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma
Principal Investigator(s): Dr. Ajai Chari

A Phase I Study of the Combination of a Selective Inhibitor of Nuclear Export (SINE), Selinexor, with Carfilzomib and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
Principal Investigator(s): Dr. Ajai Chari

Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients Who Have Enrolled on BMT CTN 0702
Principal Investigator(s): Dr. Keren Osman

A Phase I/II, Open-label, Multicenter Study of ACY-1215 administered Orally As Monotherapy and in Combination with Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma
Principal Investigator(s): Sundar Jagannath

A Phase 2b, Open-Label, Single-Arm Study Of Selinexor (KPT-330) Plus Low-Dose Dexamethasone In Patients With Multiple Myeloma Refractory To Bortezomib, Lenalidomide, Carfilzomib And Pomalidomide
Principal Investigator(s): Dr. Sundar Jagannath

Intergroup Randomized Phase II Four Arm Study in Patients > 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab + Bendamustine Followed by Rituximab Consolidation (RB -> R); Arm B = Rituximab + Bendamustine + Bortezomib Followed by Rituximab Consolidatoin (RBV -> R), Arm C = Rituximab + Bendamustine Followed by Lenalidomide + Riuximab Consolidation (RB -> LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV -> LR)
Principal Investigator(s): Dr. Samir Parekh

A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LD-DEX) versus Bortezomib and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma (MM)
Principal Investigator(s): Sundar Jagannath

A Multicenter Phase 1/2b of the Bruton’s Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination with Carfilzomib (Kyprolis) in Subjects with Relapsed or Relapsed and Refractory Multiple Myeloma
Principal Investigator(s): Ajai Chari

A Trial of Single Autologous Transplant with or without Consolidation Therapy versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma
Principal Investigator(s): Luis M. Isola

An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Daratumumab with the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Subjects with Relapsed or Refractory Multiple Myeloma
Principal Investigator(s): Dr. Ajai Chari

Phase I/Ib Pharmacokinetics Study of Oral MLN9708 Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients with Normal Renal Function or Severe Renal Impairment
Principal Investigator(s): Ajai Chari

An Open-label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination with Backbone Regimens for the Treatment of Subjects with Multiple Myeloma
Principal Investigator(s): Dr. Ajai Chari

Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of ONYX 0912 in Patients with Hematological Malignancies
Principal Investigator(s): Sundar Jagannath

An Expanded Access Program for Elotuzumab in Combination with Lenalidomide plus Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Principal Investigator(s): Dr. Sundar Jagannath